U.S. markets close in 6 hours 22 minutes
  • S&P 500

    4,141.29
    -38.47 (-0.92%)
     
  • Dow 30

    33,943.18
    -110.76 (-0.33%)
     
  • Nasdaq

    12,010.24
    -190.58 (-1.56%)
     
  • Russell 2000

    2,001.22
    +40.41 (+2.06%)
     
  • Crude Oil

    75.97
    +0.09 (+0.12%)
     
  • Gold

    1,894.90
    -35.90 (-1.86%)
     
  • Silver

    22.72
    -0.90 (-3.79%)
     
  • EUR/USD

    1.0862
    -0.0049 (-0.45%)
     
  • 10-Yr Bond

    3.5140
    +0.1180 (+3.47%)
     
  • GBP/USD

    1.2133
    -0.0096 (-0.78%)
     
  • USD/JPY

    130.2790
    +1.6750 (+1.30%)
     
  • BTC-USD

    23,376.35
    -524.68 (-2.20%)
     
  • CMC Crypto 200

    533.73
    -3.13 (-0.58%)
     
  • FTSE 100

    7,858.53
    +38.37 (+0.49%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.
Cogent Biosciences, Inc.

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.

The event will be led by Andrew Robbins, Cogent’s President and CEO, and will include a presentation by Daniel J. DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute. The speakers and additional members of Cogent leadership will be available during the Question & Answer session.

The live webcast of the event can be accessed on the Investors and Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653